Under a new federal ruling, CMS will not pay for potentially avoidable surgical site infections following cardiac implantable electronic device procedures. The new rule went into effect this month and is part of the Hospital Inpatient Prospective Payment System.
The survey includes responses from 50 hospital CEOs at academic health centers and community hospitals. The findings include the following:
• The top three CEO concerns about the inclusion of CIED-related infections as a healthcare-acquired condition were financial impact; impact on quality measures; and infection rates outpacing CIED implant rates.
• Nearly two-thirds of CEOs surveyed said their institutions had increased use of antibiotic technology to reduce the incidence of previously designated HACs, such as infections associated with vascular catheter-associated infections or catheter-associated urinary tract infections.
• At least 70 percent of CEOs surveyed planned to introduce new technologies to reduce CIED infections.
• More than 90 percent planned to use internal reporting to heighten visibility of CIED infections.
• Approximately 40 percent believed their institutions would implant fewer CIEDs in high risk patients because of the new HAC.
Learn more about TYRX.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
